跳至主要内容
临床试验/2025-524054-34-00
2025-524054-34-00招募中3 期

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

Biogen Idec Research Limited14 个研究点 分布在 7 个国家目标入组 40 人开始时间: 2026年7月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
40
试验地点
14
主要终点
1-1. Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Total Score in Treatment-Naïve Cohort. The HFMSE is a tool used to assess motor function in individuals with SMA.

研究概览

简要总结

The primary objective of the SOLAR study is to evaluate the clinical efficacy of salanersen in participants with SMA who are treatment-naïve or previously treated with risdiplam.

研究设计

分配方式
Na
主要目的
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115)
盲法
None

入排标准

年龄范围
0 years 至 64 years(0-17 Years, 18-64 Years)
接受健康志愿者

入选标准

  • Participants aged 15 to 60 years, inclusive, at the time of informed consent
  • For participants in the risdiplam-treated cohort: Willing to stop risdiplam therapy for the duration of the study. The last dose of risdiplam must be taken the day before the first dose of salanersen.
  • For participants in the risdiplam-treated cohort: No prior treatment with nusinersen, onasemnogene abeparvovec-xioi/onasemnogene abeparvovec-brve (OA), other approved DMTs for SMA or investigational drugs given for the treatment of SMA apart from risdiplam.
  • Ambulatory and nonambulatory participants. Ambulatory participants must be able to walk at least 10 meters independently without assistance and are willing and able to complete the 6 Minute Walk Test (6MWT) at Screening.
  • Participants with genetic documentation of 5q Spinal Muscular Atrophy (SMA) (homozygous gene deletion or mutation or compound heterozygous mutation).
  • Participants with clinical signs and symptoms consistent with SMA.
  • Survival motor neuron 2 (SMN2) copy number ≥
  • Participants with baseline Hammersmith Functional Motor Scale – Expanded (HFMSE) total score of ≥ 10 to ≤
  • Participants who are able to sit without using support for at least 10 seconds.
  • Participants with no prior treatment with myostatin inhibitors and a willingness to remain off concurrent myostatin inhibitor therapy for the duration of the study.
  • For participants in the treatment-naïve cohort: No prior treatment with an approved SMA Disease Modifying Therapy (DMT) or an investigational drug given for the treatment of SMA.
  • For participants in the risdiplam-treated cohort: Currently receiving risdiplam treatment and have been on once-daily 5 milligrams (mg) risdiplam treatment for at least 6 months prior to Screening.

排除标准

  • Respiratory insufficiency at Screening, defined by the medical necessity for invasive or noninvasive ventilation for > 6 hours during a 24-hour period (except for nocturnal bilevel positive airway pressure).
  • Medical necessity for a gastric feeding tube, where the majority of nutrition is provided by this route, as assessed by the site Investigator at Screening.
  • History of brain or spinal cord disease or other contraindications (e.g. severe scoliosis) that would interfere with the lumbar puncture (LP) procedures, Cerebrospinal fluid (CSF) circulation, efficacy assessments, or safety assessments (including a history of hydrocephalus or implanted shunt for CSF drainage), as assessed by the Investigator.
  • Hospitalization for surgery, a pulmonary event, or nutritional support within 2 months prior to Screening or plans to undergo elective procedures or surgeries at any time after signing the Informed Consent Form (ICF) through the end of the study. Note: If prior scoliosis surgery has been performed, it must be done at least 1 year prior to Screening.
  • Presence of an active medical issue (e.g., infection, recent fracture) that would make the participant unsuitable for inclusion, as assessed by the Investigator.
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 90 days or 5 half-lives of the treatment (if known), whichever is longer, prior to Screening. This includes neuromodulation therapy such as spinal cord stimulation.

研究组 & 干预措施

BIIB115

Test

干预措施: BIIB115 (Drug)

结局指标

主要结局

1-1. Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Total Score in Treatment-Naïve Cohort. The HFMSE is a tool used to assess motor function in individuals with SMA.

1-1. Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Total Score in Treatment-Naïve Cohort. The HFMSE is a tool used to assess motor function in individuals with SMA.

1-2. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities. [Time Frame: At Month 12]

1-2. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities. [Time Frame: At Month 12]

次要结局

  • 1-1. Percentage of Participants With ≥ 3-Point Change From Baseline in HFMSE Total Score. The HFMSE is a tool used to assess motor function in individuals with SMA.
  • 1-2. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities. [Time Frame: Up to Day 1825]
  • 2-1. Percentage of Participants With ≥ 2-Point Change From Baseline in Revised Upper Limb Module (RULM) Total Score. The RULM is developed to assess upper limb functional abilities of participants with SMA.
  • 2-2. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function. [Time Frame: Up to Day 1825]
  • 3-1. Percentage of Participants With ≥ 30-Meter Change From Baseline in 6-Minute Walk Test (6MWT) Distance (Ambulatory Participants Only).
  • 3-2. The 6MWT is a submaximal exercise test used to assess an individual’s functional exercise capacity. It measures the distance covered in 6 minutes on a flat, hard surface, providing valuable information about aerobic capacity and endurance [Time Frame: Up to Day 1825]
  • 4-1. Change From Baseline in HFMSE Total Score. The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement.
  • 4-2. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities. [Time Frame: Up to Day 1825]
  • 5. Change From Baseline in RULM Total Score. The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function. [Time Frame: Up to Day 1825]
  • 6. Change From Baseline in Total 6MWT Distance (Ambulatory Participants Only). The 6MWT is a submaximal exercise test used to assess an individual’s functional exercise capacity. It measures the distance covered in 6 minutes on a flat, hard surface, providing valuable information about aerobic capacity and endurance. [Time Frame: Up to Day 1825]
  • 7-1. Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitudes. CMAP is a well validated method for tracking disease progression in neuromuscular disorders such as SMA and amyotrophic lateral sclerosis and has been proposed as a potential biomarker of a therapeutic effect in SMA.
  • 7-2. CMAPs will be performed for the following nerve-muscle pairs: ulnar-abductor digiti minimi and peroneal-tibialis anterior. [Time Frame: Up to Day 1825]
  • 8-1. Patient Global Impression of Change (PGI-C) Score. PGI-C is a self-reported 7-point scale evaluating the participant’s perception of change in disease state since baseline.
  • 8-2. The scale ranges from 1 to 7, where 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; or 7= very much worse. Lower scores indicate clinical improvement, and higher scores indicate disease worsening. [Time Frame: Up to Day 1825]
  • 9-1. Change From Baseline in SMA Independence Scale - Upper Limb Module (SMAIS-ULM). The SMAIS-ULM is a validated tool designed to assess the level of independence in daily activities related to upper limb functionality for individuals with Type II and nonambulant Type III SMA.
  • 9-2. The 22 items assess upper limb focused tasks across 5 domains of typical daily activities (bathing/hygiene, dressing, eating/drinking, picking up/moving objects, and other tasks) scored on a 3-point scale (0 = I cannot do this at all without help; 1 = I need some help; and 2 = I do not need help). Higher scores indicate greater independence. [Time Frame: Up to Day 1825]
  • 10. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). [Time Frame: Up to Day 1825]
  • 11. Concentration of Salanersen in Cerebrospinal Fluid (CSF). [Time Frame: Up to Day 1460]
  • 12. Concentration of Salanersen in Serum. [Time Frame: Up to Day 1825]

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Clinical Trials Information Desk

Scientific

Biogen Idec Research Limited

研究点 (14)

Loading locations...

相似试验